TD Cowen analyst Marc Frahm initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating.The analyst comments "Nektar is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE